Stocks· September 08, 2026 at 08:05 PM
Authored by·Editorially reviewed
Onur Erkan YıldızFounder, Financial Engineer · CMB-licensed
Higher education in Financial Engineering and Money & Capital Markets. SPK (Turkey CMB) licence. 16 years across institutional markets, research, and quant-driven analytics.
NeutralMedium impact
AI summary
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer’s patients anticipated by year-end 2027 or first quarter of 2028
AI commentary is generated from public news feeds and is not investment advice.
Related coverage
StocksMedium impactNeutral1h
ISP Global Capital: Fort Technology Reports Record Revenue Growth and Closes Logia USA Acquisition
via GlobalNewswire
StocksMedium impactNeutral1h
Google Warns EU Regulations Will Result In Lower Search Quality
via Yahoo Finance
GOOGL
StocksMedium impactNeutral1h
DAL Stock Drops: Jefferies Sees Possible Snag To In-Cabin Experience Owing To SPCX-VSAT Spectrum Fight
via Yahoo Finance
AMZN
StocksMedium impactNeutral1h
The Trade Desk makes major reset after brutal 70% decline
via Yahoo Finance
AMZN